Can the dexamethasone intravitreal implant Ozurdex be safely administered in an out-of-operating room setting?

References

• Klein R, Moss SE, Meuer SM, et al. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol. 2008;126(4):513–518.
   PubMedGoogle Scholar
• Ding J, Wong TY. Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr Diab Rep. 2012;12(4):346–354.
   PubMed Web of Science ®Google Scholar
• Bandello F, Battaglia Parodi M, Lanzetta P, et al. Diabetic macular edema. Dev Ophthalmol. 2017;58:102–138.
   PubMedGoogle Scholar
• Ehlers JP, Fekrat S. Retinal vein occlusion: beyond the acute event. Surv Ophthalmol. 2011;56(4):281–299.
   PubMed Web of Science ®Google Scholar
• Rehak M, Wiedemann P. Retinal vein thrombosis: pathogenesis and management. J Thromb Haemost. 2010;8(9):1886–1894.
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237(4):185–222.
   PubMed Web of Science ®Google Scholar
• Coscas G, Loewenstein A, Augustin A, et al. Management of retinal vein occlusion–consensus document. Ophthalmologica. 2011;226(1):4–28.
   PubMed Web of Science ®Google Scholar
• Bressler SB, Ayala AR, Bressler NM, et al.; for the Diabetic Retinopathy Clinical Research Network. Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment. JAMA Ophthalmol. 2016;134(3):278–285.
   PubMed Web of Science ®Google Scholar
• Gonzalez VH, Campbell J, Holekamp NM, et al. Early and long-term responses to anti-vascular endothelial growth factor therapy in diabetic macular edema:analysis of protocol i data. Am J Ophthalmol. 2016;172:72–79.
   PubMed Web of Science ®Google Scholar
• Bressler NM, Beaulieu WT, Glassman AR, et al. Diabetic Retinopathy Clinical Research Network. Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol. 2018;136(3):257–269.
   PubMed Web of Science ®Google Scholar
• Dugel PU, Campbell JH, Kiss S, et al. Association between early anatomic response to anti vascular endothelial growth factor therapy and long-term outcome in diabetic macular edema: an independent analysis of protocol i study data. Retina. 2019;39(1):88–97.
   PubMed Web of Science ®Google Scholar
• Busch C, Zur D, Fraser-Bell S, et al.; for the International Retina Group. Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema. Acta Diabetol. 2018;55(8):789–796.
   PubMed Web of Science ®Google Scholar
• Hernández Martínez A, Pereira Delgado E, Silva Silva G, et al. Early versus late switch: how long should we extend the anti-vascular endothelial growth factor therapy in unresponsive diabetic macular edema patients? Eur J Ophthalmol. 2019. doi:10.1159/000506312 [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Demir G, Ozkaya A, Yuksel E, et al. Early and late switch from ranibizumab to an intravitreal dexamethasone implant in patients with diabetic macular edema in the event of a poor anatomical response. Clin Drug Investig. 2020;40(2):119–128.
   PubMed Web of Science ®Google Scholar
• Iglicki M, Zur D, Busch C, et al. Progression of diabetic retinopathy severity after treatment with dexamethasone implant: a 24-month cohort study the ‘DR-Pro-DEX study’. Acta Diabetol. 2018;55(6):541–547.
   PubMed Web of Science ®Google Scholar
• Iglicki M, Busch C, Zur D, et al. Dexamethasone implant for diabetic macular edema in naive compared with refractory eyes: the International Retina Group real-life 24-month multicenter study. The IRGREL-DEX study. Retina. 2019;39(1):44–51.
   PubMed Web of Science ®Google Scholar
• Mello Filho P, Andrade G, Maia A, et al. Effectiveness and safety of intravitreal dexamethasone implant (Ozurdex) in patients with diabetic macular edema: a real-world experience. Ophthalmologica. 2019;241(1):9–16.
   PubMed Web of Science ®Google Scholar
• Zur D, Iglicki M, Loewenstein A. The role of steroids in the management of diabetic macular edema. Ophthalmic Res. 2019;62(4):231–236.
   PubMed Web of Science ®Google Scholar
• Iglicki M, Zur D, Fung A, et al.; for the International Retina Group (IRG). TRActional DIabetic reTInal detachment surgery with co-adjuvant intravitreal dexamethasONe implant: the TRADITION STUDY. Acta Diabetol. 2019;56(10):1141–1147.
   PubMed Web of Science ®Google Scholar
• Zur D, Iglicki M, Sala-Puigdollers A, et al.; International Retina Group (IRG). Disorganization of retinal inner layers as a biomarker in patients with diabetic macular oedema treated with dexamethasone implant. Acta Ophthalmol. 2019;
   Web of Science ®Google Scholar
• Meyers L, Almeida D, Abràmoff MD. Intravitreal injection technique. A primer for ophthalmology residents and fellows; [cited 2019 Nov 25]. Available from: https://webeye.ophth.uiowa.edu/eyeforum/tutorials/intravitreal-injection/index.htm
   Google Scholar
• Grzybowski A, Told R, Sacu S, et al. 2018 update on intravitreal injections: Euretina Expert Consensus Recommendations. Ophthalmologica. 2018;239(4):181–193.
   PubMed Web of Science ®Google Scholar
• Xing L, Dorrepaal SJ, Gale J. Survey of intravitreal injection techniques and treatment protocols among retina specialists in Canada. Can J Ophthalmol. 2014;49(3):261–266.
   PubMed Web of Science ®Google Scholar
• Arias-Barquet L, Basauri-Rementeria E, Gómez-Ulla d I F. Serv clinical practice guidelines: management of intravitreal injections; [cited 2019 Nov 26]. Available from: https://serv.es/wp-content/descargasWP/documentacionMedica/Guia_SERV_02_primeraRevision.pdf
   Google Scholar
• Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravitreous injections. Retina. 2004;24(Suppl):S3–S19.
   PubMedGoogle Scholar
• Pilli S, Kotsolis A, Spaide RF, et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol. 2008;145(5):879–882.
   PubMed Web of Science ®Google Scholar
• Fenoll MA. [Arcsterile: a cost-effective luxury]. Rev Enferm. 2015;38(5):8–12.
   PubMed Web of Science ®Google Scholar
• Dossier of ArcSterile; [cited 2019 Nov 26]. Available from: https://www.imex.es/wp-content/uploads/2015/12/DOSSIER-Arc-Sterile-eng_1.pdf
   Google Scholar
• Authors not listed. International Standard. Cleanrooms and associated controlled environments; [cited 2019 Nov 26]. Available from: http://zoser.com.co/wp-content/uploads/2015/10/ISO%2014644-1%20Version%202015.pdf
   Google Scholar
• Cidad-Betegón P, Armadá-Maresca F, De la Rosa-Pérez I, et al. Arcsterile: intravitreal injections protocol. 10th Annual Congress on Controversies in Ophthalmology: Europe (COPHy EU); [cited 2020 Feb 7]. Available from: https://www.comtecmed.com/cophy/2019/Uploads/Editor/Docs/15.pdf
   Google Scholar
• Guigou S, Pommier S, Meyer F, et al. Efficacy and safety of intravitreal dexamethasone implant in patients with diabetic macular edema. Ophthalmologica. 2015;233(3–4):169–175.
   PubMed Web of Science ®Google Scholar
• Boyer DS, Yoon YH, Belfort R, Jr, et al., Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904–1914.
   PubMed Web of Science ®Google Scholar
• Spanish national Health System; [cited 2020 Feb 7]. Available from: https://www.mscbs.gob.es/organizacion/sns/libroSNS.htm
   Google Scholar
• Barkun JS. Waiting lists for surgery. Can J Surg. 2002;45(5):328–329.
   PubMed Web of Science ®Google Scholar
• Waddell JP. Wait times and health care resources. Can J Surg. 2004;47(6):405–407.
   PubMedGoogle Scholar
• Lai TY, Liu S, Das S, et al. Intravitreal injection – technique and safety. Asia Pac J Ophthalmol (Phila). 2015;4(6):321–328.
   PubMed Web of Science ®Google Scholar
• Dossarps D, Bron AM, Koehrer P, et al.; FRCR net (FRenCh Retina specialists net). Endophthalmitis after intravitreal injections: incidence, presentation, management, and visual outcome. Am J Ophthalmol. 2015;160(1):17–25.e1.
   PubMed Web of Science ®Google Scholar
• Stem MS, Todorich B, Yonekawa Y, et al. Incidence and visual outcomes of culture-proven endophthalmitis following dexamethasone intravitreal implant. JAMA Ophthalmol. 2017;135(4):379–382.
   PubMed Web of Science ®Google Scholar
• Rajesh B, Zarranz-Ventura J, Fung AT, et al.; International Ozurdex Study Group. Safety of 6000 intravitreal dexamethasone implants. Br J Ophthalmol. 2020;104(1):39–46.
   PubMed Web of Science ®Google Scholar
• VanderBeek BL, Bonaffini SG, Ma L. The association between intravitreal steroids and post-injection endophthalmitis rates. Ophthalmology. 2015;122(11):2311–2315.e1.
   PubMed Web of Science ®Google Scholar
• Freiberg FJ, Brynskov T, Munk MR, et al. Low endophthalmitis rates after intravitreal anti-vascular endothelial growth factor injections in an operation room: a retrospective multicenter study. Retina. 2017;37(12):2341–2346.
   PubMed Web of Science ®Google Scholar
• Bandello F, Cicinelli MV. 19th EURETINA congress keynote lecture: diabetic retinopathy today. Ophthalmologica. 2020. doi:10.1159/000506312 [Epub ahead of print].
   Web of Science ®Google Scholar
• Hee MR, Puliafito CA, Wong C, et al. Quantitative assessment of macular edema with optical coherence tomography. Arch Ophthalmol. 1995;113(8):1019–1029.
   PubMedGoogle Scholar
• Forooghian F, Cukras C, Meyerle CB, et al. Evaluation of time domain and spectral domain optical coherence tomography in the measurement of diabetic macular edema. Investig Ophthalmol Vis Sci. 2008;49(10):4290–4296.
   PubMed Web of Science ®Google Scholar
• Kakinoki M, Sawada O, Sawada T, et al. Comparison of macular thickness between Cirrus HD-OCT and Stratus OCT. Ophthalmic Surg Lasers Imaging. 2009;40(2):135–140.
   PubMedGoogle Scholar
• Legarreta JE, Gregori G, Punjabi OS, et al. Macular thickness measurements in normal eyes using spectral domain optical coherence tomography. Ophthalmic Surg Lasers Imaging. 2008;39(4 Suppl):S43–S9.
   PubMedGoogle Scholar
• Wang JC, Laíns I, Providência J, et al. Diabetic choroidopathy: choroidal vascular density and volume in diabetic retinopathy with swept-source optical coherence tomography. Am J Ophthalmol. 2017;184:75–83.
   PubMed Web of Science ®Google Scholar
• Willoughby AS, Chiu SJ, Silverman RK, et al. Platform-independent cirrus and spectralis thickness measurements in eyes with diabetic macular edema using fully automated software. Transl Vis Sci Technol. 2017;6(1):9.
   PubMed Web of Science ®Google Scholar